Phase i study assessing the safety and tolerability of barasertib (azd1152) with low-dose cytosine arabinoside in elderly patients with AML

Clinical Lymphoma, Myeloma and Leukemia

Volumn 13, Issue 5, 2013, Pages 559-567

  Kantarjian, Hagop M ^a   Sekeres, Mikkael A ^b   Ribrag, Vincent ^c   Rousselot, Philippe ^d   Garcia Manero, Guillermo ^a   Jabbour, Elias J ^a   Owen, Kate ^e   Stockman, Paul K ^e   Oliver, Stuart D ^e  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b TAUSSIG CANCER INSTITUTE   (United States)

^c INSTITUT GUSTAVE ROUSSY   (France)

^d CENTRE HOSPITALIER DE VERSAILLES   (France)

^e ASTRAZENECA   (United Kingdom)

Author keywords

Acute myeloid leukemia; Barasertib hQPA; Dose escalation study

Indexed keywords

BARASERTIB; CYTARABINE;

ABNORMAL LABORATORY RESULT; ACUTE GRANULOCYTIC LEUKEMIA; ACUTE HEART INFARCTION; ADULT; AGED; ALOPECIA; ANEMIA; ANORECTAL DISEASE; AREA UNDER THE CURVE; CLINICAL ARTICLE; CONFERENCE PAPER; CONFUSION; CONSTIPATION; CONTINUOUS INFUSION; COUGHING; DECREASED APPETITE; DIARRHEA; DISTRIBUTION VOLUME; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSE ESCALATION; DRUG HALF LIFE; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEBRILE NEUTROPENIA; FEMALE; FEVER; HEADACHE; HEART ATRIUM FIBRILLATION; HEMORRHOID; HUMAN; HYPERTENSION; HYPOXIA; INSOMNIA; LOW DRUG DOSE; MALE; MAXIMUM PLASMA CONCENTRATION; MAXIMUM TOLERATED DOSE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; MUSCULOSKELETAL PAIN; NAUSEA; NEUTROPENIA; OROPHARYNX PAIN; PANCYTOPENIA; PERIPHERAL EDEMA; PETECHIA; PHASE 1 CLINICAL TRIAL; PNEUMONIA; RASH; STOMATITIS; THROMBOCYTOPENIA; TREATMENT RESPONSE; URINARY TRACT INFECTION; VOMITING;

ACUTE MYELOID LEUKEMIA; BARASERTIB-HQPA; DOSE-ESCALATION STUDY;

AGE FACTORS; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYTARABINE; FEMALE; HUMANS; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; ORGANOPHOSPHATES; QUINAZOLINES; TREATMENT OUTCOME;

EID: 84884155615     PISSN: 21522650     EISSN: 21522669     Source Type: Journal    
DOI: 10.1016/j.clml.2013.03.019     Document Type: Conference Paper

References (23)

1. B. Löwenberg, J.R. Downing, and A. Burnett Acute myeloid leukemia N Engl J Med 341 1999 1051 1062
2. D. Pulte, A. Gondos, and H. Brenner Improvements in survival of adults diagnosed with acute myeloblastic leukemia in the early 21st century Haematologica 93 2008 594 600
3. J.M. Rowe, and M.S. Tallman Intensifying induction therapy in acute myeloid leukemia: has a new standard of care emerged? Blood 90 1997 2121 2126
4. H.F. Fernandez, Z. Sun, and X. Yao Anthracycline dose intensification in acute myeloid leukemia N Engl J Med 361 2009 1249 1259
5. H. Kantarjian, F. Ravandi, and S. O'Brien Intensive chemotherapy does not benefit most older patients (age 70 years or older) with acute myeloid leukemia Blood 116 2010 4422 4429
6. A.K. Burnett, D. Milligan, and A.G. Prentice A comparison of low-dose cytarabine and hydroxyurea with or without all-trans retinoic acid for acute myeloid leukemia and high-risk myelodysplastic syndrome in patients not considered fit for intensive treatment Cancer 109 2007 1114 1124
7. P. Meraldi, R. Honda, and E.A. Nigg Aurora kinases link chromosome segregation and cell division to cancer susceptibility Curr Opin Genet Dev 14 2004 29 36
8. T. Ikezoe, J. Yang, and C. Nishioka A novel treatment strategy targeting Aurora kinases in acute myelogenous leukemia Mol Cancer Ther 6 2007 1851 1857
9. N. Keen, and S. Taylor Mitotic drivers-inhibitors of the Aurora B kinase Cancer Metastasis Rev 28 2009 185 195
10. S.P. Joel, A. Oke, and N. Foot The activity of the novel Aurora kinase B inhibitor AZD1152 in acute myeloid leukaemia cells Blood 106 2005 3374
11. A. Oke, D. Pearce, and R.W. Wilkinson AZD1152 rapidly and negatively affects the growth and survival of human acute myeloid leukemia cells in vitro and in vivo Cancer Res 69 2009 4150 4158
12. E. Walsby, V. Walsh, and C. Pepper Effects of the aurora kinase inhibitors AZD1152-HQPA and ZM447439 on growth arrest and polyploidy in acute myeloid leukemia cell lines and primary blasts Haematologica 93 2008 662 669
13. R.W. Wilkinson, R. Odedra, and S.P. Heaton AZD1152, a selective inhibitor of aurora B kinase, inhibits human tumor xenograft growth by inducing apoptosis Clin Cancer Res 13 2007 3682 3688
14. D.S. Boss, P.O. Witteveen, and J. van der Sar Clinical evaluation of AZD1152, an i.v. inhibitor of Aurora B kinase, in patients with solid malignant tumors Ann Oncol 22 2011 431 437
15. B. Löwenberg, P. Muus, and G. Ossenkoppele Phase I/II study to assess the safety, efficacy, and pharmacokinetics of barasertib (AZD1152) in patients with advanced acute myeloid leukemia Blood 118 2011 6030 6036
16. K. Tsuboi, T. Yokozawa, and T. Sakura A Phase I study to assess the safety, pharmacokinetics and efficacy of barasertib (AZD1152), an Aurora B kinase inhibitor, in Japanese patients with advanced acute myeloid leukemia Leuk Res 35 2011 1384 1389
17. J.W. Vardiman, J. Thiele, and D.A. Arber The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes Blood 114 2009 937 951
18. D. Grimwade, and R.K. Hills Independent prognostic factors for AML outcome Hematology Am Soc Hematol Educ Program 2009 385 395
19. AstraZeneca.Global Policy: Bioethics. Available at: http://www. astrazeneca.com/cs/Satellite?blobcol=urldata&blobheader= application%2Fpdf&blobheadername1=Content-Disposition&blobheadername2= MDT-Type&blobheadervalue1=inline%3B+filename%3DBioethics. pdf&blobheadervalue2=abinary%3B+charset%3DUTF-8&blobkey= id&blobtable=MungoBlobs&blobwhere=1285641505329&ssbinary=true. Accessed: May 23, 2013.
20. B.D. Cheson, J.M. Bennett, and K.J. Kopecky Revised recommendations of the International Working Group for diagnosis, standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukemia J Clin Oncol 21 2003 4642 4649
21. X.G. Thomas, A. Dmoszynska, and A. Wierzbowska Results from a randomized phase III trial of decitabine versus supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed AML [Abstract] J Clin Oncol 2011 29 (15S)
22. M. Payton, T.L. Bush, and G. Chung Preclinical evaluation of AMG 900, a novel potent and highly selective pan-aurora kinase inhibitor with activity in taxane-resistant tumor cell lines Cancer Res 70 2010 9846 9854
23. K.R. Kelly, S.T. Nawrocki, and C.M. Espitia Targeting Aurora A kinase activity with the investigational agent alisertib increases the efficacy of cytarabine through a FOXO-dependent mechanism Int J Cancer 131 2012 2693 2703